Ocugen announces first patient dosed in Phase 1 OCU200 trial for DME
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...
What Marvel and DC heroes can teach us about resilience
It might seem a bit frivolous as a topic, but Jackson pointed out that Marvel and DC films reach audiences of hundreds of ...
eLife12h
Early and delayed STAT1-dependent responses drive local trained immunity of macrophages in the spleen
In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.
Recycling Today13h
Century Aluminum receives Phase One contract under DOE grant
Century Aluminum has entered Phase One of a four-phase agreement under a Department of Energy grant initiative, originally ...